血清HE4、CA125、ROMA指数在卵巢癌患者中的诊断价值  

Diagnostic value of serum HE4,CA125 and ROMA in ovarian cancer patients

作　　者：赖有行[1] 周晓莹[1] 黄瑞玉[1] 穆小萍[1] 周永贤[1] 

机构地区：[1]广东省妇幼保健院,广东广州510010

出　　处：《中国妇幼保健》2017年第1期48-50,共3页Maternal and Child Health Care of China

摘　　要：目的探讨血清肿瘤标志物人附睾分泌蛋白4(HE4)、糖类抗原125(CA125)水平和卵巢癌恶性风险模型(ROMA)在卵巢癌预测和诊断中的应用价值。方法选取2014年2月-2015年8月期间来该院就诊的卵巢癌患者55例作为卵巢癌组,选取同期接受治疗的卵巢肿瘤为良性的患者60例作为良性肿瘤组,同时选取46例健康女性作为对照组,3组均采用微粒子酶免疫化学发光法测定血清中HE4、CA125水平,并计算出ROMA指数值联合评估卵巢癌风险性。结果卵巢癌组血清HE4、CA125水平和ROMA指数值均明显高于良性肿瘤组和健康对照组,差异均有统计学意义(P<0.05);卵巢良性肿瘤组与健康对照组HE4水平和ROMA指数值比较,差异无统计学意义(P>0.05);HE4的敏感度、特异性、阳性预测值、阴性预测值均高于CA125,联合计算的ROMA指数的敏感度、特异性、阳性预测值、阴性预测值高于单一检测值。结论血清HE4、CA125及ROMA指数值对评估卵巢癌风险具有较高的临床价值,有利于卵巢癌的早期发现、早期诊断及早期治疗,值得在临床推广。Objective To explore the application value of serum human epididymis secretory protein 4（HE4）,carbohydrate antigen125（CA125） and ROMA in diagnosis and prediction of ovarian cancer.Methods From February 2014 to August 2015,55 cases with ovarian cancer in the hospital were selected as ovarian cancer group,60 cases with ovarian benign tumors were selected as benign tumor group,46 healthy women were selected as control group,CA125 and HE4 levels among the cases in the three groups were measured by micro particle enzyme immunoassay method,and ROMA index value of ovarian cancer risk was calculated.Results The levels of serum HE4,CA125 and ROMA in ovarian cancer group were significantly higher than those in benign tumor group and control group（P〈0.05）.There was no statistically significant difference in the level of HE4 and ROMA between benign tumor group and control group（P〉0.05）;the sensitivity,specificity,positive predictive value and negative predictive value of HE4 were higher than those of CA125;the sensitivity,specificity,positive predictive value and negative predictive value of joint detection were higher than those of single detection of HE4 and CA125.Conclusion The clinical value of serum HE4,CA125 and ROMA is high in the assessment of ovarian cancer risk,which is of great significance for early detection,early diagnosis and early treatment of ovarian cancer.It is worthy of clinical promotion.

关 键 词：人附睾蛋白4 糖类抗原CA125 卵巢恶性肿瘤风险模型 卵巢肿瘤 

分 类 号：R737.31[医药卫生—肿瘤]